Glycoprotein hormones (FSH, LH, TSH) have been assigned potencies based upon in vivo biological assays because
pure preparations have not been available and, due to carbohydrate moieties, considerable microheterogeneity
is present in each of these hormones. To standardize glycoprotein hormone assay systems, the World Health
Organization distributes reference preparations for each of the pituitary glycoprotein hormones. Historically,
these have been highly purified, but not chemically pure, preparations with assigned potencies based on biological
assays relative to arbitrarily selected preparations available at the time the reference materials were
established. Since the establishment of these reference preparations, it has been necessary to replace them
with additional materials, often more highly purified than the original reference, and to evaluate potencies
based upon in vitro (e.g., RIA) as well as in vivo (e.g., bioassays) assay systems. In some
cases, potencies vary as a function of the particular reference preparation used, and, in general, RIA's are
more heterogeneous than in vivo bioassays.
Definitions:
References: